Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone908-200-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.74 million
Profitability
Miscellaneous
Employees197
OptionableOptionable
Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions
What is Celldex Therapeutics' stock symbol?
Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.07. The biopharmaceutical company earned $0.94 million during the quarter, compared to the consensus estimate of $2.08 million. Celldex Therapeutics had a negative return on equity of 51.88% and a negative net margin of 1,296.96%. View Celldex Therapeutics' Earnings History.
When is Celldex Therapeutics' next earnings date?
What price target have analysts set for CLDX?
6 equities research analysts have issued 12 month target prices for Celldex Therapeutics' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Celldex Therapeutics' share price to reach $2.6667 in the next twelve months. This suggests a possible upside of 680.9% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.
What is the consensus analysts' recommendation for Celldex Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celldex Therapeutics.
What are Wall Street analysts saying about Celldex Therapeutics stock?
Here are some recent quotes from research analysts about Celldex Therapeutics stock:
- 1. According to Zacks Investment Research, "Following the discontinuation of glembatumumab vedotin studies, Celldex is focused on developing its anti-cancer pipeline candidates including CDX-301, which is being developed for the lucrative lung cancer market. Celldex also has collaborations with big pharma companies, which lend solid support as well as expertise. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, the failure of glembatumumab vedotin was a major setback. With no approved products, further pipeline setbacks will severely impact Celldex. The company depends entirely on product development, licensing agreements, contracts and grants for revenues. Shares of the company have significantly underperformed the industry in the past six months." (1/14/2019)
- 2. Cowen Inc analysts commented, "We are pleased with Endo’s beat and raise quarter as the company continues to pivot itself into a more specialized company with foci on durable brands like Xiaflex, specialty injectables and a specialty generic base business. As such, the strength in the shares seen post earnings likely indicates that investors are pleased with management’s recent actions (as are we). At the same time we continue to view current debt levels, ongoing opioid litigation, and legal liabilities as significant overhangs on the name that could stunt momentum and remain HOLD rated on ENDP shares." (8/9/2018)
- 3. Cantor Fitzgerald analysts commented, "Glemba is a Miss. The METRIC trial evaluating metastatic TNBC patients that overexpress gpNMB versus capecitibine did not achieve statistical significance, with glemba-treated patients experiencing PFS of 2.7 months versus 2.6 months for capecitibine, p=0.76. Additionally, significance was not achieved for key secondary endpoints of OR (overall response), DoR (Duration of Response) or OS (Overall Survival)." (4/17/2018)
Has Celldex Therapeutics been receiving favorable news coverage?
Media headlines about CLDX stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celldex Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the folowing people:
- Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 57)
- Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 60)
- Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 48)
- Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 47)
- Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 55)
How do I buy shares of Celldex Therapeutics?
Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celldex Therapeutics' stock price today?
One share of CLDX stock can currently be purchased for approximately $0.3415.
How big of a company is Celldex Therapeutics?
Celldex Therapeutics has a market capitalization of $58.90 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-93,030,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Celldex Therapeutics employs 197 workers across the globe.
What is Celldex Therapeutics' official website?
How can I contact Celldex Therapeutics?
Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]
MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
